Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium.

Widder J, Bol GM, Simek IM, Ehret F, Abdel-Aty H, Basic S, Chuter D, Daly J, Fairbrother P, Zeqa D, Aboubakar Nana F, Achard V, Corradini S, Correia D, De Ruysscher D, Dingemans AC, Faivre-Finn C, Gillessen S, Guren MG, Hendriks L, Kunz WG, Lecouvet FE, Levy A, Lievens Y, McDonald F, Meattini I, Oppong F, Oprea-Lager D, Palma D, Fredberg Persson G, Remon J, Vandemaele M, van Laarhoven HWM, Verkooijen HM, Visani L, Zilli T, Ost P, Guckenberger M

Open source

DOI: 10.1016/s1470-2045(26)00075-6
Published: 2026 May
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00075-6,
  title = {Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium.},
  author = {Widder J and Bol GM and Simek IM and Ehret F and Abdel-Aty H and Basic S and Chuter D and Daly J and Fairbrother P and Zeqa D and Aboubakar Nana F and Achard V and Corradini S and Correia D and De Ruysscher D and Dingemans AC and Faivre-Finn C and Gillessen S and Guren MG and Hendriks L and Kunz WG and Lecouvet FE and Levy A and Lievens Y and McDonald F and Meattini I and Oppong F and Oprea-Lager D and Palma D and Fredberg Persson G and Remon J and Vandemaele M and van Laarhoven HWM and Verkooijen HM and Visani L and Zilli T and Ost P and Guckenberger M},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00075-6},
  url = {https://doi.org/10.1016/s1470-2045(26)00075-6}
}

RIS

TY  - JOUR
TI  - Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium.
AU  - Widder J
AU  - Bol GM
AU  - Simek IM
AU  - Ehret F
AU  - Abdel-Aty H
AU  - Basic S
AU  - Chuter D
AU  - Daly J
AU  - Fairbrother P
AU  - Zeqa D
AU  - Aboubakar Nana F
AU  - Achard V
AU  - Corradini S
AU  - Correia D
AU  - De Ruysscher D
AU  - Dingemans AC
AU  - Faivre-Finn C
AU  - Gillessen S
AU  - Guren MG
AU  - Hendriks L
AU  - Kunz WG
AU  - Lecouvet FE
AU  - Levy A
AU  - Lievens Y
AU  - McDonald F
AU  - Meattini I
AU  - Oppong F
AU  - Oprea-Lager D
AU  - Palma D
AU  - Fredberg Persson G
AU  - Remon J
AU  - Vandemaele M
AU  - van Laarhoven HWM
AU  - Verkooijen HM
AU  - Visani L
AU  - Zilli T
AU  - Ost P
AU  - Guckenberger M
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00075-6
UR  - https://doi.org/10.1016/s1470-2045(26)00075-6
ER  -

APA

J, W., GM, B., IM, S., F, E., H, A., S, B., D, C., J, D., P, F., D, Z., F, A. N., V, A., S, C., D, C., D, D. R., AC, D., C, F., S, G., MG, G., L, H., WG, K., FE, L., A, L., Y, L., F, M., I, M., F, O., D, O., D, P., G, F. P., J, R., M, V., HWM, V. L., HM, V., L, V., T, Z., P, O., & M, G. (2026). Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00075-6

Source records

pubmed · retrieved 2026-09-25T22:51:08.760Z